ArticleGynecologic oncology reports2026

HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge.

Oriana Krivenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.